Prostaglandin EP4 antagonists
AssigneeAllergan, Inc.
InventorsLarry A. Wheeler, Michael E. Garst, Yanbin Liang, David F. Woodward, Achim H.-P. Krauss, Robert M. Burk, Yariv Donde, Mark Holoboski, David W. Old, June Chen
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions related to compound 1 or compound 2 or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP4 receptor, or are prostaglandin EP4 antagonists.
Claims2
A method of treating an EP4 receptor mediated condition comprising administering a therapeutically effective amount of a compound to a mammal in need thereof, wherein said compound has a formula
- or a pharmaceutically acceptable salt thereof;
- and
- wherein said EP4 receptor mediated condition is an ocular disease, wherein said ocular disease is glaucoma.
A method comprising treating glaucoma by administering to a mammal suffering from glaucoma a compound comprising
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.